• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.

作者信息

Popat Sanjay

机构信息

From the Department of Medicine, Royal Marsden Hospital, and the Section of Genomic Medicine, National Heart and Lung Institute, Imperial College, London.

出版信息

N Engl J Med. 2018 Jan 11;378(2):192-193. doi: 10.1056/NEJMe1714580.

DOI:10.1056/NEJMe1714580
PMID:29320658
Abstract
摘要

相似文献

1
Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.奥希替尼作为表皮生长因子受体（EGFR）突变的非小细胞肺癌的一线治疗药物
N Engl J Med. 2018 Jan 11;378(2):192-193. doi: 10.1056/NEJMe1714580.
2
Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy.奥希替尼用于一线表皮生长因子受体酪氨酸激酶抑制剂治疗期间进展后的表皮生长因子受体突变阳性非小细胞肺癌的成本效益评论
J Thorac Oncol. 2018 May;13(5):e83-e84. doi: 10.1016/j.jtho.2018.02.006.
3
Safety of osimertinib in EGFR-mutated non-small cell lung cancer.奥希替尼在 EGFR 突变型非小细胞肺癌中的安全性。
Expert Opin Drug Saf. 2018 Dec;17(12):1239-1248. doi: 10.1080/14740338.2018.1549222. Epub 2018 Dec 5.
4
Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy.回应：关于奥希替尼用于一线表皮生长因子受体酪氨酸激酶抑制剂治疗进展后的表皮生长因子受体突变阳性非小细胞肺癌的成本效益评论
J Thorac Oncol. 2018 May;13(5):e84-e85. doi: 10.1016/j.jtho.2018.02.017.
5
Osimertinib in EGFR Mutation–Positive Advanced NSCLC.奥希替尼用于表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌
N Engl J Med. 2018 Mar 29;378(13):1261. doi: 10.1056/NEJMc1801669.
6
Osimertinib in EGFR Mutation–Positive Advanced NSCLC.奥希替尼用于表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌
N Engl J Med. 2018 Mar 29;378(13):1261-2. doi: 10.1056/NEJMc1801669.
7
Osimertinib in EGFR Mutation–Positive Advanced NSCLC.奥希替尼用于表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌
N Engl J Med. 2018 Mar 29;378(13):1262. doi: 10.1056/NEJMc1801669.
8
Osimertinib in EGFR Mutation-Positive Advanced NSCLC.奥希替尼用于表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌
N Engl J Med. 2018 Mar 29;378(13):1262-1263. doi: 10.1056/NEJMc1801669.
9
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.奥希替尼（AZD9291）可降低表皮生长因子受体（EGFR）突变的非小细胞肺癌细胞中程序性死亡配体-1的表达水平。
Acta Pharmacol Sin. 2017 Nov;38(11):1512-1520. doi: 10.1038/aps.2017.123. Epub 2017 Sep 7.
10
Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.奥希替尼对比多西他赛联合贝伐珠单抗作为 EGFR T790M 突变型非小细胞肺癌三线治疗。
Lung Cancer. 2018 Jul;121:5-11. doi: 10.1016/j.lungcan.2018.04.012. Epub 2018 Apr 17.

引用本文的文献

1
Effect of CYP3A4 inhibitor and induction on the pharmacokinetics and safety of FHND9041, a novel EGFR T790M inhibitor, in healthy Chinese.CYP3A4抑制剂和诱导剂对新型EGFR T790M抑制剂FHND9041在中国健康受试者体内药代动力学及安全性的影响。
BMC Pharmacol Toxicol. 2025 May 7;26(1):97. doi: 10.1186/s40360-025-00930-2.
2
Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non-small-cell lung cancer.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）用于一线治疗表皮生长因子受体（EGFR）阳性转移性非小细胞肺癌的真实世界比较结果
Cancer Treat Res Commun. 2025;43:100898. doi: 10.1016/j.ctarc.2025.100898. Epub 2025 Mar 13.
3
PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.
PIM1 激酶通过调节 EGFR 突变型非小细胞肺癌中的 GSK3β 信号通路促进 EMT 相关的奥希替尼耐药。
Cell Death Dis. 2024 Sep 3;15(9):644. doi: 10.1038/s41419-024-07039-0.
4
Qualitative assessment of knowledge, attitude and practice of oncologists about precision medicine in cancer patients- study from Lahore, Pakistan.定性评估肿瘤学家对癌症患者精准医学的知识、态度和实践-来自巴基斯坦拉合尔的研究。
PLoS One. 2024 Apr 5;19(4):e0299010. doi: 10.1371/journal.pone.0299010. eCollection 2024.
5
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes.非小细胞肺癌治疗策略的个体化：基因突变和程序性死亡配体-1表达在生存结果中的作用
Cancers (Basel). 2023 Oct 31;15(21):5248. doi: 10.3390/cancers15215248.
6
Feiyanning formula modulates the molecular mechanism of osimertinib resistance in lung cancer by regulating the Wnt/β-catenin pathway.肺岩宁方通过调控Wnt/β-连环蛋白信号通路调节肺癌奥希替尼耐药的分子机制。
Front Pharmacol. 2022 Nov 29;13:1019451. doi: 10.3389/fphar.2022.1019451. eCollection 2022.
7
Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model.伴有软脑膜转移的肺腺癌的预测因素：2022年靶向治疗辅助molGPA模型
Front Oncol. 2022 Jun 10;12:903851. doi: 10.3389/fonc.2022.903851. eCollection 2022.
8
Ciclopirox Olamine Exerts Tumor-Suppressor Effects Topoisomerase II Alpha in Lung Adenocarcinoma.环吡酮胺对肺腺癌中的拓扑异构酶IIα发挥肿瘤抑制作用。
Front Oncol. 2022 Feb 18;12:791916. doi: 10.3389/fonc.2022.791916. eCollection 2022.
9
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy.非小细胞肺癌的现状：流行病学、组织学分类、靶向治疗和免疫治疗
Cancers (Basel). 2021 Sep 20;13(18):4705. doi: 10.3390/cancers13184705.
10
Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.未经 T790M 突变检测的既往 EGFR-TKI 治疗的 NSCLC 患者中奥希替尼的真实世界疗效。
J Cancer Res Clin Oncol. 2022 Aug;148(8):2099-2114. doi: 10.1007/s00432-021-03766-5. Epub 2021 Aug 26.